Adjuvant Sutent improves disease-free survival in RCC

Pfizer Inc. (NYSE:PFE) said Sutent sunitinib met the primary endpoint of significantly improving

Read the full 133 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE